Analyst Rating
based on 12 analysts
41.67%
Buy
8.33%
Hold
50.00%
Sell
Based on 12 analysts offering long term price targets for Gland Pharma Ltd. An average target of ₹1983.58
Source: S&P Global Market Intelligence
Gland Pharma Ltd Share analysis
Gland Pharma Ltd price forecast by 12 analysts
Upside of7.72%
High
₹3120
Target
₹1983.58
Low
₹1214
Gland Pharma Ltd target price ₹1983.58, a slight upside of 7.72% compared to current price of ₹1810.05. According to 12 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Gland Pharma Ltd revenue growth forecast
Expected growth rate Q1, FY2026:24.43%
Forecast
Actual
Including amortisation and stock based compensations
Gland Pharma Ltd EPS growth forecast
EPS estimate Q1, FY2026:54.37%
Forecast
Actual
Source: S&P Global Market Intelligence
Performance
Day's Low
Day's High
₹1,801₹1,849.4552 Week's Low
52 Week's High
₹1,475.05₹2,220.95
| Returns % | |
| 1 Month Return | -6.09 % |
| 3 Month Return | + 0.73 % |
| 1 Year Return | + 9.55 % |
| Market Stats | |
| Previous Close | ₹1,841.50 |
| Open | ₹1,845.00 |
| Volume | 2.31L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹30,339.03Cr |
Key Statistics
| P/E Ratio | 42.01 |
| PEG Ratio | -28.77 |
| Market Cap | ₹30,339.03 Cr |
| P/B Ratio | 3.37 |
| EPS | 46.9 |
| Dividend Yield | 1.09 |
| Sector | Pharmaceuticals |
| ROE | 12.31 |
Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹30,339.03 Cr | 0.24% | 0.50 | ₹772 Cr | ₹5,664 Cr | |
| HOLD | ₹1,45,188.75 Cr | 49.12% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,13,699.02 Cr | 58.95% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
| HOLD | ₹43,659.82 Cr | 12% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
| BUY | ₹1,33,377.76 Cr | 53.07% | 0.50 | ₹4,155 Cr | ₹25,774 Cr |
Mutual Fund Holdings
Company Information
Gland Pharma's operations include the development, manufacture, and marketing of a wide range of injectable drugs and active pharmaceutical ingredients. The company's product portfolio includes antibiotics, anti-emetics, anti-diabetics, anti-epileptics, and other therapeutic categories. Its top products include cephalosporins, penicillins, and other injectable antibiotics.
Gland Pharma is well known for its popular brands, such as Cephalosporin, Penicillin, and Amikacin. These brands have been widely used in hospitals and clinics across India, as well as in other countries. In addition, the company has developed and launched a wide range of generic and branded injectables, including Cefazolin, Cefuroxime, and Amikacin.
Share Price: ₹1810.05 per share as on 19 Sep, 2024 04:01 PM
Market Capitalisation: ₹30,339.03Cr as of today
Revenue: ₹1,401.71Cr as on June 2024 (Q2 24)
Net Profit: ₹143.76Cr as on June 2024 (Q2 24)
Listing date: 20 Nov, 2020
Chairperson Name: Yiu Kwan Stanley Lau
| Organisation | Gland Pharma Ltd |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Gland Pharma Ltd
Director Qiyu Chen Exits Gland Pharma Board - 27 Aug, 2024
Qiyu Chen, a member of Gland Pharma's board of directors, will leave his position effective August 30 due to not receiving security clearance from the Ministry of Home Affairs.
Gland Pharma Reports Mixed Financial Performance - 15 Aug, 2024
Gland Pharma's shares rose nearly 2% to Rs. 2,007.95. The company reported a 16% YoY revenue increase but a 25.7% YoY decline in net profit. Mutual funds hold a 30% stake.
Gland Pharma Reports Mixed Q1 FY25 Results - 10 Aug, 2024
In Q1 FY25, Gland Pharma's revenue rose 16% year-over-year to Rs. 1,402 crore, while net profit fell 26% to Rs. 144 crore. Promoter stake decreased from 57.86% to 51.83%. Shares closed at Rs. 2,052.55, up 1.31%.
Gland Pharma Faces Earnings Decline and Analyst Downgrades - 07 Aug, 2024
Gland Pharma's Q1 results showed a 25.94% profit decline, leading to a 4% drop in shares. Analysts have mixed views, with Motilal Oswal maintaining a Buy rating at Rs 2,440, while Nomura downgraded to Reduce with a target of Rs 1,819.
Gland Pharma Reports Decline in Profit Despite Revenue Growth - 06 Aug, 2024
Gland Pharma's Q1 FY25 results show a 26% drop in net profit to ₹143.8 crore, while revenue increased 16% to ₹1,401 crore, driven by the US market. The company remains optimistic about future growth opportunities and is exploring strategic collaborations. Analysts had estimated a profit of ₹214 crore, indicating a miss on expectations.
USFDA Issues Observations to Gland Pharma's Facility - 05 Aug, 2024
The United States Food and Drug Administration (USFDA) conducted a surprise inspection of Gland Pharma's Pashamylaram facility, resulting in three procedural 483 Observations. Shares of the company fell by 1.75%.
Gland Pharma Approaches Ex-Date for First Ever Dividend - 04 Aug, 2024
Gland Pharma Ltd's board of directors recommended a final dividend of Rs 20 per equity share, with the record date set for August 16, 2024. The company is also set to announce its Q1 results on August 6, 2024. Gland Pharma's stock has gained 5.33% in the past week and delivered a robust 17.45% return over the last month.
Gland Pharma's Hyderabad Facility Receives 3 Observations from USFDA - 03 Aug, 2024
Gland Pharma's Hyderabad facility received three procedural observations from the US FDA during an inspection. The company will submit corrective and preventive actions within the required timeframe. The observations are not related to data integrity and are non-recurring. Gland Pharma reported a 145% rise in consolidated net profit at Rs 192.4 crore in Q4FY24, with revenue of Rs 1,537.5 crore. Shares closed marginally higher at Rs 2,126.
Gland Pharma Receives Three Observations from US FDA - 02 Aug, 2024
The US FDA issued a Form 483 with three observations to Gland Pharma after an unannounced inspection of its Pashamylaram facility. The observations are procedural and not related to data integrity, and the company will submit corrective actions within the stipulated period.
Insights on Gland Pharma Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTMF Holding Up
Mutual Funds have increased holdings from 23.01% to 30.53% in Jun 2024 quarter
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 3.59% to 6.88% in Jun 2024 quarter
NO EFFECTAgainst Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 142.7% return, outperforming this stock by 195.5%
- NO EFFECT
Against Peers
In the last 1 year, Torrent Pharmaceuticals Ltd has given 78.3% return, outperforming this stock by 68.8%
NEGATIVE IMPACTPrice Dip
In the last 3 years, GLAND stock has moved down by -52.8%
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, 192.42 Cr → 143.76 Cr (in ₹), with an average decrease of 25.3% per quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 13.32% to 8.45% in Jun 2024 quarter
- NEGATIVE IMPACT
Promoter Holding Down
Promoters have decreased holdings from 57.86% to 51.83% in Jun 2024 quarter
- NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 3 quarters, 1.58K Cr → 1.45K Cr (in ₹), with an average decrease of 4.1% per quarter
Company Financials
Index Inclusions
Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 51.83% | ||
| Foreign Institutions | 6.88% | 91.69 | |
| Mutual Funds | 30.53% | 32.70 | |
| Retail Investors | 8.45% | ||
| Others | 2.3% | 3.48 |
Key Indicators
Gland Pharma Ltd Valuation
Gland Pharma Ltd in the last 5 years
Lowest (18.84x)
May 22, 2023
Today (42.01x)
September 18, 2024
Industry (58.50x)
September 18, 2024
Highest (67.14x)
August 12, 2021
Earnings and Dividends
Gland Pharma Ltd Earnings Results
Gland Pharma Ltd’s net profit fell -25.94% since last year same period to ₹143.76Cr in the Q1 2024-2025. On a quarterly growth basis, Gland Pharma Ltd has generated -25.29% fall in its net profits since last 3-months.
Read More about Earnings ResultsGland Pharma Ltd Dividends May,2024
In the quarter ending March 2024, Gland Pharma Ltd has declared dividend of ₹20 - translating a dividend yield of 1.09%.
Read More about Dividends
Technicals Summary
Bearish
Neutral
Bullish
Gland Pharma Ltd is currently in a Bearish trading position according to technical analysis indicators.
Frequently Asked Questions
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Gland Pharma Ltd shares.
Gland Pharma Ltd (GLAND) share price today is ₹1810.05
Gland Pharma Ltd is listed on NSE
Gland Pharma Ltd is listed on BSE
- Today’s highest price of Gland Pharma Ltd is ₹1849.45.
- Today’s lowest price of Gland Pharma Ltd is ₹1801.
PE Ratio of Gland Pharma Ltd is 42.01
PE ratio = Gland Pharma Ltd Market price per share / Gland Pharma Ltd Earnings per share
Today’s traded volume of Gland Pharma Ltd(GLAND) is 2.31L.
Today’s market capitalisation of Gland Pharma Ltd(GLAND) is ₹30339.03Cr.
| Gland Pharma Ltd(GLAND | Price |
|---|---|
52 Week High | ₹2220.95 |
52 Week Low | ₹1475.05 |
Gland Pharma Ltd(GLAND) share price is ₹1810.05. It is down -18.50% from its 52 Week High price of ₹2220.95
Gland Pharma Ltd(GLAND) share price is ₹1810.05. It is up 22.71% from its 52 Week Low price of ₹1475.05
| Gland Pharma Ltd(GLAND | Returns |
|---|---|
1 Day Returns | -31.45% |
1 Month Returns | -6.09% |
3 Month Returns | 0.73% |
1 Year Returns | 9.55% |